Prevention of bleomycin-induced pulmonary fibrosis by vaccination with the Tocilizumab mimotope

References

• Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993 Feb 15;53(4):851–11.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 2012;52:199–219. doi:10.1146/annurev-pharmtox-010611-134715
   PubMed Web of Science ®Google Scholar
• Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017 Nov;77(17):1865–79. doi:10.1007/s40265-017-0829-7.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008 Mar 22;371(9617):998–1006. doi:10.1016/S0140-6736(08)60454-7.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012 Dec 20;367(25):2385–95. doi:10.1056/NEJMoa1112802.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000 Jan 1;95(1):56–61. doi:10.1182/blood.V95.1.56.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K. et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005 Oct 15;106(8):2627–32. doi:10.1182/blood-2004-12-4602.
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology. 2004 Apr;126(4):989–96. discussion 947. doi:10.1053/j.gastro.2004.01.012.
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010 Feb;62(2):542–52. doi:10.1002/art.27221. PMID: 20112381; PMCID: PMC3057537.
   PubMed Web of Science ®Google Scholar
• Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M, Fain O. Club Rhumatismes et Inflammation, and SNFMI. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev. 2013 Oct;12(12):1143–9. doi:10.1016/j.autrev.2013.06.019.
   PubMed Web of Science ®Google Scholar
• Spiera R, Unizony SH, Bao M, Luder Y, Han J, Pavlov A, Stone JH. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum. 2021 Apr;51(2):469–476. doi:10.1016/j.semarthrit.2021.03.006.
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Berthelot JM, Cornec D, Renaudineau Y, Marhadour T, Jousse-Joulin S, Querellou S, Garrigues F, De Bandt M, Gouillou M. et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016 Aug;75(8):1506–10. doi:10.1136/annrheumdis-2015-208742.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018 Dec;77(12):1720–1729. doi:10.1136/annrheumdis-2018-213920.
   PubMed Web of Science ®Google Scholar
• Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, Huang S, Khanna D; focuSsced investigators. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2021 Jul;73(7):1301–10. doi:10.1002/art.41668.
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004 Jan;4(1):71–8. doi:10.1038/nrc1256.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009 Mar;9(3):162–74. doi:10.1038/nri2506.
   PubMed Web of Science ®Google Scholar
• Santer FR, Malinowska K, Culig Z, Cavarretta IT. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer. 2010 Feb 18;17(1):241–53. doi:10.1677/ERC-09-0200.
   PubMed Web of Science ®Google Scholar
• Coomes EA, Haghbayan H. Interleukin-6 in covid-19: a systematic review and meta-analysis. Rev Med Virol. 2020 Nov;30(6):1–9. doi:10.1002/rmv.2141.
   PubMed Web of Science ®Google Scholar
• Karampitsakos T, Papaioannou O, Tsiri P, Katsaras M, Katsimpris A, Kalogeropoulos AP, Malakounidou E, Zarkadi E, Tsirikos G, Georgiopoulou V. et al. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Clin Microbiol Infect. 2023 Mar;29(3):372–378. doi:10.1016/j.cmi.2022.10.015.
   PubMed Web of Science ®Google Scholar
• Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017 Sep 2;13(9):1972–88. doi:10.1080/21645515.2017.1316909.
   PubMed Web of Science ®Google Scholar
• Huynh TK, Ostergaard A, Egsmose C, Madsen OR. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014 Jan 20;8:93–9. doi:10.2147/PPA.S55156.
   PubMed Web of Science ®Google Scholar
• Adams TE. Tolerance to self-antigens in transgenic mice. Mol Biol Med. 1990;7:341–57.
   PubMedGoogle Scholar
• Felici F, Luzzago A, Folgori A, Cortese R. Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the bordetella pertussis toxin from phage peptide libraries. Gene. 1993 Jun 15;128(1):21–7. doi:10.1016/0378-1119(93)90148-v.
   PubMed Web of Science ®Google Scholar
• Luzzago A, Felici F, Tramontano A, Pessi A, Cortese R. Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides. Gene. 1993 Jun 15;128(1):51–7. doi:10.1016/0378-1119(93)90152-s.
   PubMed Web of Science ®Google Scholar
• Yang L, Guo J, Yu N, Liu Y, Song H, Niu J, Gu Y. Tocilizumab mimotope alleviates kidney injury and fibrosis by inhibiting IL-6 signaling and ferroptosis in UUO model. Life Sci. 2020 Nov 15;261:118487. doi:10.1016/j.lfs.2020.118487.
   PubMed Web of Science ®Google Scholar
• Yang L, Xing R, Li C, Liu Y, Sun L, Liu X, Wang Y. Active immunization with tocilizumab mimotopes induces specific immune responses. BMC Biotechnol. 2015 Jun 2;15:46. doi:10.1186/s12896-015-0161-9.
   PubMed Web of Science ®Google Scholar
• Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988 Apr;41(4):467–70. doi:10.1136/jcp.41.4.467.
   PubMed Web of Science ®Google Scholar
• Long KK, Montano M, Pavlath GK. Sca-1 is negatively regulated by TGF-beta1 in myogenic cells. FASEB J. 2011 Apr;25(4):1156–65. doi:10.1096/fj.10-170308.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol. 2014 Feb;26(1):88–96. doi:10.1016/j.smim.2014.01.009.
   PubMed Web of Science ®Google Scholar
• Hu L, Yu Y, Huang H, Fan H, Hu L, Yin C, Li K, Fulton DJ, Chen F. Epigenetic regulation of interleukin 6 by histone acetylation in macrophages and its role in paraquat-induced pulmonary fibrosis. Front Immunol. 2017 Jan 30;7:696. doi:10.3389/fimmu.2016.00696.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sang X, Shao R, Qin H, Chen X, Xue Z, Li L, Wang Y, Zhu Y, Chang Y. et al. Xuanfei Baidu decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway. J Ethnopharmacol. 2022 Jan 30;283:114701. doi:10.1016/j.jep.2021.114701.
   PubMed Web of Science ®Google Scholar
• Epstein Shochet G, Brook E, Bardenstein-Wald B, Shitrit D. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. Respir Res. 2020 Feb 18;21(1):56. doi:10.1186/s12931-020-1319-0.
   PubMed Web of Science ®Google Scholar
• Xue Z, Zhao F, Sang X, Qiao Y, Shao R, Wang Y, Gao S, Fan G, Zhu Y, Yang J. Combination therapy of tanshinone IIA and puerarin for pulmonary fibrosis via targeting IL6-JAK2-STAT3/STAT1 signaling pathways. Phytother Res. 2021 Oct;35(10):5883–5898. doi:10.1002/ptr.7253.
   PubMed Web of Science ®Google Scholar
• Pulivendala G, Bale S, Godugu C. Honokiol: a polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-β/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo. Toxicol Appl Pharmacol. 2020 Mar 15;391:114913. doi:10.1016/j.taap.2020.114913.
   PubMed Web of Science ®Google Scholar
• Le TT, Karmouty-Quintana H, Melicoff E, Le TT, Weng T, Chen NY, Pedroza M, Zhou Y, Davies J, Philip K. et al. Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis. J Immunol. 2014 Oct 1;193(7):3755–68. doi:10.4049/jimmunol.1302470. Epub 2014 Aug 29.
   PubMed Web of Science ®Google Scholar
• El-Kashef DH, Youssef ME, Nasr M, Alrouji M, Alhajlah S, AlOmeir O, El Adle Khalaf N, Ghaffar DMA, Jamil L, Abdel-Nasser ZM. et al. Pimitespib, an HSP90 inhibitor, augments nifuroxazide-induced disruption in the IL-6/STAT3/HIF-1α autocrine loop in rats with bleomycin-challenged lungs: evolutionary perspective in managing pulmonary fibrosis. Biomed Pharmacother. 2022 Sep;153:113487. doi:10.1016/j.biopha.2022.113487.
   PubMed Web of Science ®Google Scholar
• Han D, Gong H, Wei Y, Xu Y, Zhou X, Wang Z, Feng F. Hesperidin inhibits lung fibroblast senescence via IL-6/STAT3 signaling pathway to suppress pulmonary fibrosis. Phytomedicine. 2023 Apr;112:154680. doi:10.1016/j.phymed.2023.154680.
   PubMed Web of Science ®Google Scholar
• Moodley YP, Scaffidi AK, Misso NL, Keerthisingam C, McAnulty RJ, Laurent GJ, Mutsaers SE, Thompson PJ, Knight DA. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. Am J Pathol. 2003 Jul;163(1):345–54. doi:10.1016/S0002-9440(10)63658-9.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Antoniou K, Kreuter M, Evison M, Blum TG, Poletti V, Grigoriu B, Vancheri C, Spagnolo P, Karampitsakos T. et al. 2021 Jan 25. The DIAMORFOSIS (DIAgnosis and management of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Res. 7(1):00529–2020. doi:10.1183/23120541.00529-2020.
   PubMedGoogle Scholar
• Tzouvelekis A, Karampitsakos T, Kourtidou S, Bouros E, Tzilas V, Katsaras M, Antonou C, Dassiou M, Bouros D. Impact of depression on patients with idiopathic pulmonary fibrosis. Front Med. 2020 Feb 7;7:29. doi:10.3389/fmed.2020.00029.
   Web of Science ®Google Scholar
• Karampitsakos T, Galaris A, Chrysikos S, Papaioannou O, Vamvakaris I, Barbayianni I, Kanellopoulou P, Grammenoudi S, Anagnostopoulos N, Stratakos G. et al. Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis. Respir Res. 2023 Nov 14;24(1):279. doi:10.1186/s12931-023-02551-x.
   PubMed Web of Science ®Google Scholar
• Karampitsakos T, Juan-Guardela BM, Tzouvelekis A, Herazo-Maya JD. Precision medicine advances in idiopathic pulmonary fibrosis. EBioMedicine. 2023 Sep;95:104766. doi:10.1016/j.ebiom.2023.104766.
   PubMed Web of Science ®Google Scholar
• Phan SH. Biology of fibroblasts and myofibroblasts. Proc Am Thorac Soc. 2008 Apr 15;5(3):334–7. doi:10.1513/pats.200708-146DR.
   PubMedGoogle Scholar
• Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014 May 27;5:123. doi:10.3389/fphar.2014.00123.
   PubMed Web of Science ®Google Scholar
• Wong-Ekkabut J, Xu Z, Triampo W, Tang IM, Tieleman DP, Monticelli L. Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study. Biophys J. 2007 Dec 15;93(12):4225–36. doi:10.1529/biophysj.107.112565.
   PubMed Web of Science ®Google Scholar
• Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, Tang M, Liu Z, Anderson B, Thamburaj K. et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020 Oct 27;11(1):5424. doi:10.1038/s41467-020-19193-y.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Galluzzi L. Fighting resilient cancers with iron. Trends Cell Biol. 2018 Feb;28(2):77–78. doi:10.1016/j.tcb.2017.11.007.
   PubMed Web of Science ®Google Scholar
• Morré DJ, Morré DM. Non-mitochondrial coenzyme Q. Biofactors. 2011 Sep-Oct;37(5):355–60. doi:10.1002/biof.156.
   PubMed Web of Science ®Google Scholar
• Ernster L, Forsmark-Andrée P. Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig. 1993;71(8 Suppl):S60–5. doi: 10.1007/BF00226842. PMID: 8241707.
   PubMedGoogle Scholar
• Lee C. Collaborative power of Nrf2 and PPARγ activators against metabolic and drug-induced oxidative injury. Oxid Med Cell Longev. 2017;2017:1378175. doi:10.1155/2017/1378175
   PubMed Web of Science ®Google Scholar
• Lee J, Lim JW, Kim H. Lycopene inhibits IL-6 expression by upregulating NQO1 and HO-1 via activation of Nrf2 in ethanol/lipopolysaccharide-stimulated pancreatic acinar cells. Antioxid (Basel). 2022 Mar 8;11(3):519. doi:10.3390/antiox11030519.
   PubMedGoogle Scholar
• Luo JF, Zhou H, Lio CK. Akebia saponin D inhibits the inflammatory reaction by inhibiting the IL-6-STAT3-DNMT3b Axis and activating the Nrf2 pathway. Molecules. 2022 Sep 22;27(19):6236. doi:10.3390/molecules27196236.
   PubMed Web of Science ®Google Scholar
• Narimiya T, Kanzaki H, Yamaguchi Y, Wada S, Katsumata Y, Tanaka K, Tomonari H. Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression. Bone Rep. 2019 Nov 1;11:100228. doi:10.1016/j.bonr.2019.100228.
   PubMedGoogle Scholar